Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. · 2018
Read Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors. by Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6185986.txt.
Description
Méndez-Blanco and co-authors wrote a review in Experimental and Molecular Medicine on sorafenib resistance in liver cancer. Sorafenib is a multi-action drug and the standard first-line treatment for advanced hepatocellular carcinoma. It slows growth, cuts blood supply, and promotes tumor cell death. Long-term success is low because resistant cells emerge.
The review focuses on hypoxia-inducible factors, proteins that respond to low oxygen. By shrinking tumor vessels, sorafenib itself deepens oxygen shortage. Hypoxia programs then select cells that thrive in that setting. High HIF-1 alpha and HIF-2 alpha mark poor outlook in patients. The authors map this feedback loop and what it means for future combination treatments.
Catalog record
| CREATOR | Méndez-Blanco C, Fondevila F, García-Palomo A, González-Gallego J, Mauriz JL. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |